Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals, Inc.

Tigris Pharmaceuticals focuses on acquiring, developing and commercializing innovative specialty care therapies with emphasis on oncology, pain, inflammation, acute and supportive care.

Building on its core competencies in clinical development, regulatory affairs, safety and commercialization, Tigris licenses or acquires rights to compounds in various stages of clinical development as well as in-market products.

Press Release

May 26, 2011
Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients » Read

September 28, 2010
Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board » Read

September 28, 2010
Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement » Read


	ASCO Annual Meeting \| June 4-8, 2010 Chicago, IL Poster Presentation: Phase I Accelerated Dose-Escalating Safety and Pharmacokinetic (PK) Study of Aryl-Hydrocarbon Receptor-Mediated Aminoflavone Prodrug, AFP464, in Advanced Solid Tumors The 8th International Symposium on Targeted Anticancer Therapies \| March 4-6, 2010 Bethesda, MD Poster Presentation: Phase I Accelerated Dose-Escalating Safety and Pharmacokinetic (PK) Study of GGTi-2418, a Novel Geryanylgeryanyltransferase I Inhibitor in Patients with Refractory Solid Tumors

©2010 Tigris Pharmaceuticals, Inc. Privacy Policy